× Thanks for reading! Log in to continue. Enjoy more articles by logging in or creating a free account. No credit card required. Log in Sign up {{featured_button_text}}

Shares of Exact Sciences Corp. stock took a leap on Tuesday after the Madison company reported second-quarter revenues from its Cologuard colorectal cancer test more than doubled those from a year ago, and the number of patients using Cologuard topped expectations.

Exact’s stock jumped 40 percent, to $17.47 a share, in early activity and ended the day at $16.21, up $3.75, 30.1 percent higher than Monday’s close at $12.46. Volume was high as 29.4 million shares were traded compared to the average daily volume of 4.5 million over the past three months.

Exact Sciences reported revenue of $21.2 million, with about 54,000 completed Cologuard tests, for the second quarter that ended June 30, up from $8.1 million in revenue, with 21,000 completed tests, for the 2015 second quarter.

Exact received 40,000 completed Cologuard tests in the first quarter and had anticipated 48,000 in the second quarter. The company now projects it will get 65,000 tests in the third quarter and continues to expect more than 240,000 for the full year.